CredoScientia - Bibliothèque

Screening the advantageous population for liver cancer undergoing yttrium-90 microsphere selective internal radiation therapy.

Yttrium-90 microsphere selective internal radiation therapy (SIRT), also known as transarterial radioembolization, has become one of the pivotal treatments for liver cancer, particularly for selected …

Thérapies de Conversion

Liang, L., Liang, Y., Huang, W., Guo, Y., Huang, J., Zhou, J., Lin, L., Nie, X., Cai, M., & Zhu, K. (2026). Screening the advantageous population for liver cancer undergoing yttrium-90 microsphere selective internal radiation therapy.. Liver Res, 10(1), 61-70. https://doi.org/10.1016/j.livres.2025.12.002

01/03/2026 Lire →

Advancing hepatology through innovation and integration: 's vision for 2026.

Thérapies de Conversion

Du, Z. C., Wang, K. C., Wang, M. D., Cai, L., Zhong, J. H., & Yang, T. (2026). Advancing hepatology through innovation and integration: 's vision for 2026.. ILIVER, 5(1), 100224. https://doi.org/10.1016/j.iliver.2026.100224

01/03/2026 Lire →

Conversion therapy for advanced hepatocellular carcinoma following complete response to transarterial radioembolization combined with atezolizumab and bevacizumab.

BACKGROUND: The current Barcelona Clinic Liver Cancer (BCLC) classification recommends systemic treatment with atezolizumab and bevacizumab as the first-line therapy for advanced hepatocellular carcin…

Thérapies de Conversion

Popovic, P., Kalamutova, A., Djokic, M., Cuderman, A., Boltezar, G., & Trotovsek, B. (2026). Conversion therapy for advanced hepatocellular carcinoma following complete response to transarterial radioembolization combined with atezolizumab and bevacizumab.. Radiol Oncol, 60(1), 40-48. https://doi.org/10.2478/raon-2026-0015

01/03/2026 Lire →

Preoperative chemotherapy in colorectal peritoneal metastatic disease - a real-world observational cohort study.

OBJECTIVES: The effects of preoperative chemotherapy have been poorly studied in colorectal cancer with peritoneal metastases (CRC-PM). This study evaluated preoperative chemotherapy from the first mu…

Thérapies de Conversion

Cashin, P. H., Frühling, P., Grönlund, P., Graf, W., Nygren, P., & Ghanipour, L. (2026). Preoperative chemotherapy in colorectal peritoneal metastatic disease - a real-world observational cohort study.. Pleura Peritoneum, 11(1), 1-10. https://doi.org/10.1515/pp-2025-0035

01/03/2026 Lire →

Conversion Therapy for cT4b and M1 Esophageal Squamous Cell Carcinoma: A Comprehensive Systematic Review.

Conversion therapy, defined as curative-intent surgery or chemoradiotherapy after induction therapy, is gaining attention in patients with initially unresectable esophageal squamous cell carcinoma due…

Thérapies de Conversion

Booka, E., & Takeuchi, H. (2026). Conversion Therapy for cT4b and M1 Esophageal Squamous Cell Carcinoma: A Comprehensive Systematic Review.. Ann Gastroenterol Surg, 10(2), 294-304. https://doi.org/10.1002/ags3.70104

01/03/2026 Lire →

Deep learning-assisted tumor radiomic dynamics on MRI predict pathological complete response in HCC undergoing immune-based therapy followed by hepatectomy.

BACKGROUND AND AIMS: Pathological complete response (pCR) following conversion therapy for initially unresectable hepatocellular carcinoma (uHCC) remains challenging to predict preoperatively. This st…

Thérapies de Conversion

Zhou, S. Q., Wang, L. N., Wu, L. F., Sun, L. Y., Yang, Y. C., Yang, Z. Y., Wang, Z. Y., He, T., Li, F., Chen, L. L., Li, H., Zhu, X. D., Shen, Y. H., Huang, C., Ji, Y., Gao, Q., Zhou, J., Fan, J., Chen, Y. J., … China, L. i. v. e. r. . C. a. n. c. e. r. . S. t. u. d. y. . G. r. o. u. p. . Y. o. u. n. g. . I. n. v. e. s. t. i. g. a. t. o. r. s. . (. C. L. E. A. P. ). (2026). Deep learning-assisted tumor radiomic dynamics on MRI predict pathological complete response in HCC undergoing immune-based therapy followed by hepatectomy.. Hepatology. https://doi.org/10.1097/HEP.0000000000001724

26/02/2026 Lire →

Survival Outcomes, Recurrence Patterns, and Its Corresponding Therapeutic Management after Conversion Therapy Followed by Curative Resection for Hepatocellular Carcinoma: A Real-World Study.

INTRODUCTION: There remains a scarcity of research focusing on long-term survival, the administration of adjuvant therapy, and recurrence following conversion resection in patients suffering from init…

Thérapies de Conversion

Xiao, R., Yang, Z., Zheng, Z., Liu, N., Yu, W., Lin, Q., Chen, J., Wang, J., Zhou, Z., Zhang, Y., Chen, M., & Hu, D. (2026). Survival Outcomes, Recurrence Patterns, and Its Corresponding Therapeutic Management after Conversion Therapy Followed by Curative Resection for Hepatocellular Carcinoma: A Real-World Study.. Liver Cancer. https://doi.org/10.1159/000550954

23/02/2026 Lire →

Prognostic outcomes of surgery vs. non-surgery in initially unresectable HCC with successful conversion via ICI + TKI therapy.

BACKGROUND: No consensus exists on optimal post-conversion therapy for initially unresectable hepatocellular carcinoma (uHCC) patients responding to a combination of immune checkpoint inhibitors (ICIs…

Thérapies de Conversion

Sun, Z., Wang, Y., Tan, Z., Zhou, J., Chen, X., Li, O., & Peng, C. (2026). Prognostic outcomes of surgery vs. non-surgery in initially unresectable HCC with successful conversion via ICI + TKI therapy.. BMC Gastroenterol, 26(1). https://doi.org/10.1186/s12876-026-04677-w

13/02/2026 Lire →

[Guidelines for diagnosis and treatment of hepatocellular carcinoma with portal vein tumor thrombus in China(2026 edition)].

Hepatocellular carcinoma with portal vein tumor thrombus (PVTT) has a high incidence and an extremely poor prognosis. Current international guidelines still exhibit discrepancies in the diagnosis and …

Thérapies de Conversion

Chinese, A. s. s. o. c. i. a. t. i. o. n. . o. f. . L. i. v. e. r. . C. a. n. c. e. r. . a. n. d. . C. h. i. n. e. s. e. . M. e. d. i. c. a. l. . D. o. c. t. o. r. . A. s. s. o. c. i. a. t. i. o. n. (2026). [Guidelines for diagnosis and treatment of hepatocellular carcinoma with portal vein tumor thrombus in China(2026 edition)].. Zhonghua Yi Xue Za Zhi, 106, 41-55. https://doi.org/10.3760/cma.j.cn112137-20251211-03271

12/02/2026 Lire →

Addressing the missing stair: Conversion culture in mental health ecosystems.

The author wants to direct attention to the persistent otherisation of queer/trans people in mental health ecosystems that breeds conversion culture ‒ a system of values that looks at gender/sexual di…

Thérapies de Conversion

Chatterjee, A. (2026). Addressing the missing stair: Conversion culture in mental health ecosystems.. Indian J Med Ethics. https://doi.org/10.20529/IJME.2026.006

05/02/2026 Lire →

Tislelizumab and Hypofractionated Radiotherapy plus Nab-Paclitaxel/Gemcitabine as Conversion Therapy for BRPC/LAPC: A Phase II Trial with Dynamic Biomarker Monitoring.

PURPOSE: The optimal conversion treatment for patients with borderline resectable pancreatic cancer or locally advanced pancreatic cancer (BRPC/LAPC) remains unclear. In this study, we present the eff…

Thérapies de Conversion

Ni, J., Sun, Y., Cheng, H., Bai, X., Tong, F., Zhang, X., Wang, X., Mao, L., Li, G., Shen, S., Kong, W., He, J., Li, A., Chen, J., Tang, M., Chen, B., Li, Q., Gu, Q., Lu, Z., … Du, J. (2026). Tislelizumab and Hypofractionated Radiotherapy plus Nab-Paclitaxel/Gemcitabine as Conversion Therapy for BRPC/LAPC: A Phase II Trial with Dynamic Biomarker Monitoring.. Clin Cancer Res, 32(3), 516-527. https://doi.org/10.1158/1078-0432.CCR-25-2461

04/02/2026 Lire →

How to Integrate Surgery into the Multidisciplinary Treatment of Liver-Only Metastatic Colorectal Cancer.

Colorectal liver metastases (CRLM) represent a major determinant of prognosis in patients with metastatic colorectal cancer and account for a substantial proportion of cancer-related mortality worldw…

Thérapies de Conversion

Pérez-Santiago, L., Huntley, P. a. s. c. u. a. l. . D., Sánchez, L. a. r. a. . J. S., Huerta, M., & Dorcaratto, D. (2026). How to Integrate Surgery into the Multidisciplinary Treatment of Liver-Only Metastatic Colorectal Cancer.. Cancers (Basel), 18(3). https://doi.org/10.3390/cancers18030489

02/02/2026 Lire →